Head and Neck Cancer

ECOG 1302: Phase III Randomized, Placebo-Controlled Trial of Docetaxel
Versus Docetaxel Plus ZD1839 (Iressa, gefitinib) in Performance Status 2
or Previously Treated Patients with Recurrent or Metastatic Head and
Neck Cancer, Lillian Pliner, MD, Principal Investigator

Paradigm: A Randomized Phase III Trial Comparing Sequential Therapy
with TPF/Chemoradiation (ST) to Cisplatin-based Chemoradiotherapy with
Accelerated Concomitant Boost Radiotherapy (CRT) for Locally Advanced
Squamous Cell Cancer of the Head and Neck, Lillian Pliner, MD, Principal
Investigator

ECOG 1304: Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341

(Velcade™) in Combination with Irinotecan or PS-341 Alone Followed by the

Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent

or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),

Lillian Pliner, MD, Principal Investigator

Breast Cancer

ACOZOG Z1031: A Randomized Phase III Trial Comparing 16 to 18 Weeks of
Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg) or Anstrozole
(1 mg) in Postmenopausal Women with Clinical Stage II and Stage III
Estrogen Receptor Positive Breast Cancer, Robert Wieder, MD, PhD,
Principal Investigator

CALGB 40101: Cyclophosphamide and Doxorubicin (CA x 4 Cycles) versus
Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women
with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study,
Lillian Pliner, MD, Principal Investigator

NSABP B-36: (Phase III) A Clinical Trial OF Adjuvant Therapy Comparing
Six Cycles of 5-Fluoroaucil, Epirubicin and Cylophosphamide (FEC) to
Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with
Node-Negative Breast Cancer, Margarette Bryan, MD, Principal
Investigator

SWOG 0230: Phase II Trial of LHRH Analog Administration During
Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early
State, Hormone-Receptor Negative Breast Cancer, Robert Wieder, MD, PhD,
Principal Investigator

SWOG 0500: A Randomized Phase III Trial to Test the Strategy of
Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer
in Patients who Have Elevated Circulating Tumor Cell Levels at First
Follow-Up Assessment. Robert Wieder, MD, PhD

Cancer Control Studies

MAP.3 (ExCel Study): A Phase III Randomized Study of Exemestane Versus

Placebo in Postmenopasual Women at Increased Risk of Developing Breast Cancer.

Norman Lasser, MD, PhD, FAHA, Principal Investigator, Contact Barbara Miller,

Clinical Research Associate, 973-972-6107